DK1480985T3 - Salt af benzensulfonsyre med clopidogrel og anvendelse af denne til fremstilling af farmaceutiske formuleringer - Google Patents
Salt af benzensulfonsyre med clopidogrel og anvendelse af denne til fremstilling af farmaceutiske formuleringerInfo
- Publication number
- DK1480985T3 DK1480985T3 DK04700011T DK04700011T DK1480985T3 DK 1480985 T3 DK1480985 T3 DK 1480985T3 DK 04700011 T DK04700011 T DK 04700011T DK 04700011 T DK04700011 T DK 04700011T DK 1480985 T3 DK1480985 T3 DK 1480985T3
- Authority
- DK
- Denmark
- Prior art keywords
- clopidogrel
- salt
- preparation
- pharmaceutical formulations
- benzenesulfonic acid
- Prior art date
Links
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 title abstract 7
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 title abstract 6
- 229960003009 clopidogrel Drugs 0.000 title abstract 6
- 150000003839 salts Chemical class 0.000 title abstract 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 title 1
- 229940092714 benzenesulfonic acid Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 abstract 2
- 239000003463 adsorbent Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 238000001556 precipitation Methods 0.000 abstract 2
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 abstract 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 229940127218 antiplatelet drug Drugs 0.000 abstract 1
- 230000001966 cerebroprotective effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10305984A DE10305984A1 (de) | 2003-02-13 | 2003-02-13 | Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen |
| PCT/EP2004/001369 WO2004072084A1 (de) | 2003-02-13 | 2004-02-13 | Salz der benzolsulfonsäure mit clopidogrel und dessen verwendung zur herstellung pharmazeutischer formulierungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1480985T3 true DK1480985T3 (da) | 2005-06-06 |
Family
ID=32797377
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04700011T DK1480985T3 (da) | 2003-02-13 | 2004-02-13 | Salt af benzensulfonsyre med clopidogrel og anvendelse af denne til fremstilling af farmaceutiske formuleringer |
| DK04710847T DK1592694T3 (da) | 2003-02-13 | 2004-02-13 | Partikler med aktivt stof med clopidogrel eller et farmaceutisk forligeligt salt deraf |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04710847T DK1592694T3 (da) | 2003-02-13 | 2004-02-13 | Partikler med aktivt stof med clopidogrel eller et farmaceutisk forligeligt salt deraf |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20050256152A1 (es) |
| EP (4) | EP1595884B1 (es) |
| JP (1) | JP2006515338A (es) |
| KR (3) | KR100805176B1 (es) |
| AT (3) | ATE512153T1 (es) |
| BR (1) | BRPI0407430A (es) |
| CA (2) | CA2481848C (es) |
| DE (5) | DE10305984A1 (es) |
| DK (2) | DK1480985T3 (es) |
| ES (2) | ES2282848T3 (es) |
| MX (1) | MXPA05007557A (es) |
| PL (2) | PL378572A1 (es) |
| PT (2) | PT1480985E (es) |
| SI (2) | SI1592694T1 (es) |
| WO (2) | WO2004072085A2 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1350511B1 (en) * | 2000-12-25 | 2008-09-10 | Daiichi Sankyo Company, Limited | Medicinal compositions containing aspirin |
| DE10305984A1 (de) | 2003-02-13 | 2004-09-02 | Helm Ag | Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen |
| EP1618111B1 (en) * | 2003-04-25 | 2014-12-24 | Cadila Healthcare Limited | Salts of clopidogrel and process for preparation |
| US8907090B2 (en) * | 2003-11-03 | 2014-12-09 | Cadila Healthcare Limited | Processes for preparing different forms of (S)-(+)-Clopidogrel bisulfate |
| WO2005080890A1 (de) * | 2004-02-24 | 2005-09-01 | Siegfried Generics International Ag | Pharmakologisch akzeptierbare salze von clopidogrel |
| KR100563455B1 (ko) * | 2004-04-09 | 2006-03-23 | 한미약품 주식회사 | 결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물 |
| EP1732932B1 (en) * | 2004-04-09 | 2012-03-21 | Hanmi Holdings Co., Ltd. | Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same |
| ZA200608569B (en) * | 2004-04-20 | 2007-12-27 | Sanofi Aventis | Polymorphic forms of methyl (+)-(S)-alpha- (2-chlorophenyl)-6, 7-dinydrothieno[3,2-C] pyridine-5(4H) acetate hydrobromide, clopidrogel hydrobromide |
| ZA200608035B (en) * | 2004-04-20 | 2008-07-30 | Sanofi Aventis | Clopidogrel salt and polymorphic forms thereof |
| EP1802280A4 (en) * | 2004-10-14 | 2008-02-20 | Reddys Lab Ltd Dr | CLOPIDOGREL COMPOSITIONS |
| TWI358407B (en) * | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
| EP1934229B1 (en) | 2005-09-05 | 2012-09-26 | Cadila Healthcare Limited | Processes for the preparation of different forms of (s)-(+)-clopidogrel besylate |
| WO2007054968A2 (en) * | 2005-09-20 | 2007-05-18 | Torrent Pahrmaceuticals Limited | Novel pharmaceutical compositions of clopidogrel mesylate |
| EP1926736A4 (en) * | 2005-09-21 | 2010-08-25 | Chong Kun Dang Pharm Corp | NEW RESINATE COMPLEX OF S-CLOPIDOGREL AND METHOD FOR THE PRODUCTION THEREOF |
| KR100791687B1 (ko) * | 2006-02-27 | 2008-01-03 | 채종근 | 결정성 클로피도그렐 설포살리실산 염을 포함하는 제제 |
| KR100945062B1 (ko) * | 2006-03-22 | 2010-03-05 | 한미약품 주식회사 | 클로피도그렐 1,5-나프탈렌디술폰산염 및 이의 수화물의제조방법 |
| KR100834967B1 (ko) * | 2006-08-11 | 2008-06-03 | 에스케이케미칼주식회사 | 여액의 라세미화 반응에 의한 ｓ-(＋)-클로피도그렐의고수율 제조방법 |
| EP1900358A1 (en) * | 2006-09-16 | 2008-03-19 | Cimex Pharma AG | Pharmaceutical formulations comprising clopidogrel |
| ATE498626T1 (de) * | 2006-09-25 | 2011-03-15 | Adamed Sp Zoo | Neues clopidogrel-salz und seine kristallinen formen |
| CN100400035C (zh) * | 2006-10-18 | 2008-07-09 | 深圳信立泰药业股份有限公司 | 氯吡格雷硫酸盐的固体制剂及其制备方法 |
| WO2008060934A2 (en) * | 2006-11-14 | 2008-05-22 | Acusphere, Inc. | Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration |
| EP2089396B1 (en) * | 2006-11-24 | 2011-06-22 | Cadila Healthcare Limited | A process for preparing (s)-(+)-clopidogrel base and its salts |
| WO2008081473A2 (en) * | 2006-12-29 | 2008-07-10 | Cadila Healthcare Limited | Process for preparing clopidogrel |
| KR20150041173A (ko) | 2007-04-27 | 2015-04-15 | 사이덱스 파마슈티칼스, 인크. | 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법 |
| KR20090022616A (ko) * | 2007-08-31 | 2009-03-04 | 한올제약주식회사 | 베실산클로피도그렐 함유 경구투여용 약제 |
| KR100920932B1 (ko) * | 2007-12-05 | 2009-10-20 | 한림제약(주) | 결정형의 클로피도그렐 벤젠술폰산염의 제조방법 |
| EP2107061A1 (en) | 2008-04-02 | 2009-10-07 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of optically enriched clopidogrel |
| KR101743591B1 (ko) | 2009-05-13 | 2017-06-20 | 사이덱스 파마슈티칼스, 인크. | 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법 |
| WO2012123958A1 (en) | 2011-02-14 | 2012-09-20 | Cadila Healthcare Limited | Highly pure salts of clopidogrel free of genotoxic impurities |
| CN102285996A (zh) * | 2011-03-30 | 2011-12-21 | 天津红日药业股份有限公司 | 一种苯磺酸氯吡格雷晶型ⅱ及其制备方法和用途 |
| CN102199161B (zh) * | 2011-03-30 | 2013-07-03 | 天津红日药业股份有限公司 | 一种苯磺酸氯吡格雷晶型ⅰ及其制备方法和用途 |
| HUP1400294A2 (hu) | 2014-06-13 | 2015-12-28 | Skillpharm Kft | Clopidogrel új alkalmazása |
| CN104193762B (zh) * | 2014-08-04 | 2017-02-15 | 浙江车头制药股份有限公司 | 一种制备苯磺酸氯吡格雷晶型ⅲ的方法 |
| CN115327005B (zh) * | 2022-08-12 | 2024-01-26 | 成都施贝康生物医药科技有限公司 | 一种氧化氯吡格雷有关物质的检测方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2530247B1 (fr) * | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
| FR2623810B2 (fr) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| FR2740686B1 (fr) * | 1995-11-03 | 1998-01-16 | Sanofi Sa | Formulation pharmaceutique lyophilisee stable |
| US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
| RU2270695C2 (ru) * | 1999-03-17 | 2006-02-27 | Дайити Фармасьютикал Ко., Лтд. | Фармацевтическая композиция |
| DE10109763A1 (de) * | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
| DE10153078A1 (de) * | 2001-10-30 | 2003-05-22 | Degussa | Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen |
| IL166593A0 (en) * | 2002-08-02 | 2006-01-15 | Racemization and enantiomer separation of clopidogrel | |
| DE10305984A1 (de) | 2003-02-13 | 2004-09-02 | Helm Ag | Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen |
| EP1618111B1 (en) * | 2003-04-25 | 2014-12-24 | Cadila Healthcare Limited | Salts of clopidogrel and process for preparation |
-
2003
- 2003-02-13 DE DE10305984A patent/DE10305984A1/de not_active Withdrawn
-
2004
- 2004-02-13 SI SI200430313T patent/SI1592694T1/sl unknown
- 2004-02-13 BR BR0407430-0A patent/BRPI0407430A/pt not_active IP Right Cessation
- 2004-02-13 DE DE502004003680T patent/DE502004003680D1/de not_active Expired - Lifetime
- 2004-02-13 PT PT04700011T patent/PT1480985E/pt unknown
- 2004-02-13 JP JP2006500030A patent/JP2006515338A/ja active Pending
- 2004-02-13 AT AT05009790T patent/ATE512153T1/de active
- 2004-02-13 PT PT04710847T patent/PT1592694E/pt unknown
- 2004-02-13 DE DE202004021381U patent/DE202004021381U1/de not_active Ceased
- 2004-02-13 US US10/510,578 patent/US20050256152A1/en not_active Abandoned
- 2004-02-13 PL PL378572A patent/PL378572A1/pl not_active Application Discontinuation
- 2004-02-13 KR KR1020047016562A patent/KR100805176B1/ko active IP Right Grant
- 2004-02-13 DK DK04700011T patent/DK1480985T3/da active
- 2004-02-13 PL PL04373512A patent/PL373512A1/xx not_active Application Discontinuation
- 2004-02-13 ES ES04710847T patent/ES2282848T3/es not_active Expired - Lifetime
- 2004-02-13 EP EP05009790A patent/EP1595884B1/de not_active Expired - Lifetime
- 2004-02-13 EP EP05009789A patent/EP1586575A3/de not_active Withdrawn
- 2004-02-13 EP EP04710847A patent/EP1592694B1/de not_active Revoked
- 2004-02-13 WO PCT/EP2004/001370 patent/WO2004072085A2/de active IP Right Grant
- 2004-02-13 DE DE202004021399U patent/DE202004021399U1/de not_active Expired - Lifetime
- 2004-02-13 MX MXPA05007557A patent/MXPA05007557A/es active IP Right Grant
- 2004-02-13 SI SI200430001T patent/SI1480985T1/xx unknown
- 2004-02-13 AT AT04710847T patent/ATE361305T1/de active
- 2004-02-13 CA CA002481848A patent/CA2481848C/en not_active Expired - Fee Related
- 2004-02-13 DK DK04710847T patent/DK1592694T3/da active
- 2004-02-13 EP EP04700011A patent/EP1480985B1/de not_active Revoked
- 2004-02-13 KR KR1020067018596A patent/KR20060103472A/ko not_active Application Discontinuation
- 2004-02-13 KR KR10-2004-7016868A patent/KR20050008692A/ko not_active Application Discontinuation
- 2004-02-13 WO PCT/EP2004/001369 patent/WO2004072084A1/de active Application Filing
- 2004-02-13 DE DE502004000002T patent/DE502004000002D1/de not_active Revoked
- 2004-02-13 ES ES04700011T patent/ES2236679T3/es not_active Expired - Lifetime
- 2004-02-13 CA CA002468089A patent/CA2468089A1/en not_active Abandoned
- 2004-02-13 AT AT04700011T patent/ATE290535T1/de not_active IP Right Cessation
-
2005
- 2005-04-25 US US11/113,467 patent/US20050203122A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1480985T3 (da) | Salt af benzensulfonsyre med clopidogrel og anvendelse af denne til fremstilling af farmaceutiske formuleringer | |
| WO2008131149A3 (en) | Crystal forms of saxagliptin and processes for preparing same | |
| WO2005123049A3 (en) | A pharmaceutical composition for increasing the mitochondrial genesis | |
| NO20071290L (no) | Enantiomert rene aminoheteroarylforbindelser som protein kinase inhibitorer | |
| WO2006002348A3 (en) | Solid and crystalline ibandronic acid | |
| WO2005033099A3 (en) | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof | |
| MX2009005664A (es) | D-isoglutamil-d-triptofano cristalino, y la sal monoamonica de d-isoglutamil-d-triptofano. | |
| JP2005528466A5 (es) | ||
| Balasubramanian et al. | Active site-directed synthetic thrombin inhibitors: synthesis, in vitro and in vivo activity profile of BMY 44621 and analogs. An examination of the role of the amino group in the D-Phe-Pro-Arg-H series | |
| WO2007011951A3 (en) | Purification of paricalcitol | |
| NO20076682L (no) | Nye pyridinanaloger | |
| DK1373207T3 (da) | Nyt amlodipincamsylat og fremgangsmåde til fremstilling heraf | |
| CA3159172A1 (en) | Masp-2 inhibitors and methods of use | |
| ATE541037T1 (de) | Verfahren zur trennung und reinigung von nukleinsäure | |
| FIU20020420U0 (fi) | Tamsulosiinin sulfonaattisuolalla diastereomerisesti rikastettu sakka tai liuos joka aikaansaadaan menetelmällä tamsulosiinin ja siihen liittyvien yhdisteiden liuottamisella | |
| DK1960521T3 (da) | Fremgangsmåde og test kit til separation, oprensning og genvinding af lang- og kortkædede nukleinsyrer | |
| BR9811527A (pt) | Método para a produção de amÈnia | |
| CN104628649A (zh) | 一种2-(α-羟基戊基)苯甲酰胺衍生物及其制备方法、制剂与应用 | |
| Budt et al. | HIV protease inhibitor HOE/BAY 793, structure-activity relationships in a series of C2-symmetric diols | |
| WO2006074919A3 (de) | 3 -AMINO- 6-ARYL (BZW.6-HETEROARYL) -THIENO [2 , 3-B] PYRIDIN-2-CARBONSÄUREAMIDE, DIESE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN UND IHRE VERWENDUNG ALS INHIBITOREN DER TNFα-FREISETZUNG | |
| AR054128A1 (es) | Derivados del acido 6,7-dihidro-5h-imidazo(1, 2- a)imidazol-3-sulfonico | |
| NO20061290L (no) | Nye forbindelser | |
| WO2007052302A3 (en) | Removal of pyridine and pyridine analogs from reaction mass containing sucrose esters | |
| WO2007069050A3 (en) | Processes for the preparation of alfuzosin | |
| WO2003039482A3 (en) | Polymorphs of fexofenadine base |